XEPTAGEN SpA is engaged in the discovery and validation of novel molecular markers in order to produce innovative diagnostic kits for cancer early detection, monitoring, and evaluation of response to therapy. By exploiting the natural immune response to early stage cancer and the proprietary platform technology Combinatorial Proteomic®, XEPTAGEN has discovered predictive, prognostic and early response tumor markers that lead to an earlier and much more accurate detection of developing carcinomas. Our mission includes creating innovative tools that improve the clinical management of cancer patients.
Company Details
- Employees
- 6
- Founded
- -
- Address
- Via Delle Industrie, 9, Porto Marghera,venezia 30175,italy
- Industry
- Biotechnology
- Website
- http://www.xeptagen.com
- Keywords
- Biotechnology, Biomarkers, Personalized Medicine, In-Vitro Diagnostics, Non-alcoholic steatohepatitis (NASH).
- HQ
- Porto Marghera, Venezia
Xeptagen S.p.a. Questions
Xeptagen S.P.A.'s website is http://www.xeptagen.com
Xeptagen S.P.A.'s LinkedIn profile is https://it.linkedin.com/company/xeptagen
Xeptagen S.P.A. has
6 employees.
View email and phone details for 6
employees at Xeptagen S.P.A..
Xeptagen S.P.A.'s industry is
Biotechnology
Xeptagen S.P.A.'s top competitors are
Ustem,
Adaptyv,
Fidia Pharma,
Experteam Srl,
Alce Biotech,
Doulix,
Officinae Bio, Part Of Maravai Lifesciences,
Vivabiocell,
Provolut,
Explora Biotech Srl.
Xeptagen S.P.A.'s categories are Biotechnology
Xeptagen S.P.A.'s founding year is 2001
